Clene plans to submit a New Drug Application for CNM-Au8 in ALS by late 2025 and initiate a Phase 3 trial. Clene Inc. announced its plans to submit a New Drug Application (NDA) for CNM-Au8® for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results